J&J goes 'nuc'lear with $1.75 billion buyout of Alios BioPharma

Johnson & Johnson will buy South San Francisco’s Alios BioPharma Inc. in a $1.75 billion cash deal that will boost the big pharmaceutical company’s profile in hepatitis C and other virus fighters...